- Report
- October 2024
- 191 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- March 2025
- 175 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- March 2025
- 175 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- March 2025
- 175 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- July 2024
- 150 Pages
Global
From €3579EUR$3,750USD£2,999GBP
- Drug Pipelines
- April 2024
- 180 Pages
Global
From €2863EUR$3,000USD£2,399GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1432EUR$1,500USD£1,199GBP
- Clinical Trials
- April 2024
- 80 Pages
Global
From €1432EUR$1,500USD£1,199GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1193EUR$1,250USD£1,000GBP
- Report
- September 2023
- 110 Pages
Global
From €5679EUR$5,950USD£4,758GBP
- Report
- June 2023
- 180 Pages
Global
From €5679EUR$5,950USD£4,758GBP
- Report
- August 2022
- 119 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- August 2022
- 115 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- November 2023
- 140 Pages
Global
From €4247EUR$4,450USD£3,558GBP
- Report
- November 2023
- 353 Pages
Global
From €9067EUR$9,500USD£7,597GBP
- Report
- April 2023
- 180 Pages
Global
From €7158EUR$7,500USD£5,997GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2625EUR$2,750USD£2,199GBP
- Report
- April 2023
- 147 Pages
Global
From €4723EUR$4,949USD£3,957GBP

Everolimus is a drug used in the treatment of breast cancer. It is an mTOR inhibitor, which works by blocking the activity of a protein that helps cancer cells grow and divide. It is used in combination with other drugs to treat advanced or metastatic breast cancer. Everolimus is also used to treat hormone receptor-positive, HER2-negative breast cancer that has spread to other parts of the body. It is typically used in combination with other drugs, such as letrozole or fulvestrant.
Everolimus is available in tablet form and is taken orally. It is usually taken once daily, with or without food. Common side effects of Everolimus include nausea, vomiting, diarrhea, fatigue, and mouth sores.
In the Everolimus market, some of the major players include Novartis, Pfizer, AstraZeneca, and Merck. Other companies involved in the market include Amgen, Teva Pharmaceuticals, and Eli Lilly. Show Less Read more